1021437-95-5

Basic information

• Product Name: methyl (2R,4S,7S)-7-cyclohexyl-23-methoxy-12,12-dimethyl-6,9-dioxo-20-{[(trifluoromethyl)sulfonyl]oxy}-3,4,6,7,8,9,12,13,14,15-decahydro-2H,11H-16,18-etheno-2,5-methanopyrido[4,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxylate
• Synonyms: methyl (2R,4S,7S)-7-cyclohexyl-23-methoxy-12,12-dimethyl-6,9-dioxo-20-{[(trifluoromethyl)sulfonyl]oxy}-3,4,6,7,8,9,12,13,14,15-decahydro-2H,11H-16,18-etheno-2,5-methanopyrido[4,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxylate
• CAS NO: 1021437-95-5
• Molecular Weight: 729.772
• Mol File: 1021437-95-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl (2R,4S,7S)-7-cyclohexyl-23-methoxy-12,12-dimethyl-6,9-dioxo-20-{[(trifluoromethyl)sulfonyl]oxy}-3,4,6,7,8,9,12,13,14,15-decahydro-2H,11H-16,18-etheno-2,5-methanopyrido[4,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (2R,4S,7S)-7-cyclohexyl-23-methoxy-12,12-dimethyl-6,9-dioxo-20-{[(trifluoromethyl)sulfonyl]oxy}-3,4,6,7,8,9,12,13,14,15-decahydro-2H,11H-16,18-etheno-2,5-methanopyrido[4,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxylate(1021437-95-5)
• EPA Substance Registry System: methyl (2R,4S,7S)-7-cyclohexyl-23-methoxy-12,12-dimethyl-6,9-dioxo-20-{[(trifluoromethyl)sulfonyl]oxy}-3,4,6,7,8,9,12,13,14,15-decahydro-2H,11H-16,18-etheno-2,5-methanopyrido[4,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxylate(1021437-95-5)

Safety Data

• Hazardous Substances Data: 1021437-95-5(Hazardous Substances Data)

Upstream product

• 1021437-77-3 1-tert-butyl 2-methyl (2S,4R)-4-[(7-methoxy-2-oxo-6-vinyl-1,2-dihydroquinolin-4-yl)oxy]pyrrolidine-1,2-dicarboxylate 
• 1021437-79-5 methyl (4R)-4-[(7-methoxy-2-oxo-6-vinyl-1,2-dihydroquinolin-4-yl)oxy]-L-prolinate hydrochloride 
• 19056-40-7 4-bromo-3-methoxyaniline 
• 1021437-83-1 methyl (2R,4S,7S,14E)-7-cyclohexyl-23-methoxy-12,12-dimethyl-6,9,20-trioxo-3,4,6,7,8,9,12,13,19,20-decahydro-2H,11H-16,18-etheno-2,5-methanopyrido[4,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxylate 
• 358-23-6 trifluoromethylsulfonic anhydride 
• 1021437-85-3 methyl (2R,4S,7S)-7-cyclohexyl-23-methoxy-12,12-dimethyl-6,9,20-trioxo-3,4,6,7,8,9,12,13,14,15,19,20-dodecahydro-2H,11H-16,18-etheno-2,5-methanopyrido[4,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxylate 

Downstream Products

• 1021438-56-1 methyl (2R,4S,7S)-7-cyclohexyl-23-methoxy-12,12-dimethyl-20-(methylamino)-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2H,11H-16,18-etheno-2,5-methanopyrido[4,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxylate 
• 1021438-60-7 (3R,5S,8S)-8-cyclohexyl-18-methoxy-13,13-dimethyl-7,10-dioxo-22-(2-phenylethyl)-2,11-dioxa-6,9,21-triazatetracyclo[15.6.2.1(3,6).0(20,24)]hexacosa-1⁽²³⁾,17,19,21,24-pentaene-5-carboxylic acid 
• 1103535-14-3 C₄₂H₅₄N₆O₉S 
• 1415245-62-3 C₄₇H₅₉N₅O₁₀S 
• 1415245-63-4 C₄₇H₅₉N₅O₁₀S 
• 1415245-81-6 (2R,4S,7S)-7-cyclohexyl-23-methoxy-20-(4-methoxyphenyl)-12,12-dimethyl-6,9-dioxo-3,4,6,7,8,9,12,13,14,15-decahydro-2H,11H-16,18-etheno-2,5-methanopyrido[4,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxylic acid 
• 1415245-64-5 C₄₆H₅₆FN₅O₉S 
• 1415245-65-6 C₄₅H₅₆N₆O₉S 
• 1021437-42-2 ethyl [(3R,5S,8S)-8-cyclohexyl-5-{[((1R,2S)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)amino]carbonyl}-18-methoxy-13,13-dimethyl-7,10-dioxo-2,11-dioxa-6,9,21-triazatetracyclo[15.6.2.1(3,6).0(20,24)]hexacosa-1⁽²³⁾,17,19,21,24-pentaen-22-yl]methylcarbamate 
• 1103535-60-9 methyl (16S,19S,21R)-16-cyclohexyl-25-methoxy-11,11-dimethyl-14,17-dioxo-9,10,11,12,14,15,16,17,20,21-decahydro-8H,19H-5,7-etheno-18,21-methanoimidazo[1',2':1,6]pyrido[4,3-k][1,10,3,6]dioxadiazacyclononadecine-19-carboxylate 
• 1021437-37-5 (2R,4S,7S)-7-cyclohexyl-N-((1R,2S)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-23-methoxy-12,12-dimethyl-6,9-dioxo-20-piperidin-1-yl-3,4,6,7,8,9,12,13,14,15-decahydro-2H,11H-16,18-(ethanediylidene)-2,5-methanopyrido[4,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxamide 

Relevant articles and documents

Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease

A series of macrocyclic compounds containing 2-substituted-quinoline moieties have been discovered and shown to exhibit excellent HCV NS3/4a genotype 3a and genotype 1b R155K mutant activity while maintaining the high rat liver exposure. Cyclization of the 2-substituted quinoline substituent led to a series of tricyclic P2 compounds which also display superb gt3a potency.